Gold
CAS 7440-57-5
Gold (CAS 7440-57-5) is a pharmaceutical compound with 0 bioactivity targets and 2,261 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Gold is linked to DTXSID3064697 in DSSTox identifiers.
View industrial chemical data →Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal cramps | gold | LLT | C0000729 |
| Abdominal discomfort | gold | PT | C0232487 |
| Abdominal pain | gold | PT | C0000737 |
| Agranulocytosis | gold | LLT | C0001824 |
| Agranulocytosis | gold | PT | C0001824 |
| Albuminuria | gold | LLT | C0001925 |
| Albuminuria | gold | PT | C0001925 |
| Alopecia | gold | LLT | C0002170 |
| Alopecia | gold | PT | C0002170 |
| Anaphylactic shock | gold | LLT | C0002792 |
| Anaphylactic shock | gold | PT | C0002792 |
| Anaphylactic shock | gold | PT | C0002792 |
| Anaphylactoid reaction | gold | LLT | C0340865 |
| Anaphylactoid reaction | gold | PT | C0340865 |
| Anorexia | gold | LLT | C0003123 |
| Aplastic anaemia | gold | LLT | C0002874 |
| Aplastic anaemia | gold | PT | C0002874 |
| Arthralgia | gold | LLT | C0003862 |
| Arthralgia | gold | PT | C0003862 |
| Body temperature increased | gold | LLT | C0015967 |
| Body temperature increased | gold | PT | C0015967 |
| Bronchitis | gold | LLT | C0006277 |
| Bronchitis | gold | PT | C0006277 |
| Chrysiasis | gold | LLT | C0333604 |
| Chrysiasis | gold | PT | C0333604 |
| Colitis ulcerative | gold | PT | C0009324 |
| Confusional state | gold | LLT | C0009676 |
| Confusional state | gold | PT | C0009676 |
| Convulsion | gold | LLT | C0036572 |
| Convulsion | gold | PT | C0036572 |
| Decreased appetite | gold | PT | C0232462 |
| Dermatitis | gold | PT | C0011603 |
| Dermatitis exfoliative | gold | LLT | C0011606 |
| Dermatitis exfoliative | gold | PT | C0011606 |
| Diarrhoea | gold | LLT | C0011991 |
| Diarrhoea | gold | PT | C0011991 |
| Dizziness | gold | LLT | C0012833 |
| Dizziness | gold | PT | C0012833 |
| Dizziness | gold | PT | C0012833 |
| Dysgeusia | gold | PT | C0013378 |
| Eczema | gold | LLT | C0013595 |
| Eczema | gold | PT | C0013595 |
| Encephalitis | gold | LLT | C0014038 |
| Encephalitis | gold | PT | C0014038 |
| Encephalopathy | gold | LLT | C0085584 |
| Encephalopathy | gold | PT | C0085584 |
| Enterocolitis | gold | LLT | C0014356 |
| Enterocolitis | gold | PT | C0014356 |
| Eosinophilia | gold | LLT | C0014457 |
| Eosinophilia | gold | PT | C0014457 |
| Erythema | gold | LLT | C0041834 |
| Erythema | gold | PT | C0041834 |
| Eye disorder | gold | LLT | C0015397 |
| Eye disorder | gold | PT | C0015397 |
| Feeling abnormal | gold | PT | C1443060 |
| Fibrosis | gold | LLT | C0016059 |
| Fibrosis | gold | PT | C0016059 |
| Flushing | gold | LLT | C0016382 |
| Flushing | gold | PT | C0016382 |
| Gastrointestinal discomfort | gold | LLT | C1096250 |
| Gastrointestinal disorder | gold | PT | C0017178 |
| Glomerulonephritis | gold | LLT | C0017658 |
| Glomerulonephritis | gold | PT | C0017658 |
| Guillain-Barre syndrome | gold | LLT | C0018378 |
| Guillain-Barre syndrome | gold | PT | C0018378 |
| Haematuria | gold | LLT | C0018965 |
| Haematuria | gold | PT | C0018965 |
| Hallucination | gold | LLT | C0018524 |
| Hallucination | gold | PT | C0018524 |
| Hepatic failure | gold | LLT | C0085605 |
| Hepatic failure | gold | PT | C0085605 |
| Hepatitis | gold | LLT | C0019158 |
| Hepatitis | gold | PT | C0019158 |
| Hyperhidrosis | gold | PT | C0020458 |
| Inflammation | gold | LLT | C0021368 |
| Inflammation | gold | PT | C0021368 |
| Interstitial lung disease | gold | PT | C0206062 |
| Interstitial pneumonia | gold | LLT | C0206061 |
| Iritis | gold | LLT | C0022081 |
| Iritis | gold | PT | C0022081 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Gold used for in pharmaceutical contexts?
Gold (CAS 7440-57-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Gold?
Gold has 2,261 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal discomfort, Abdominal distension, Abdominal pain, Abdominal pain upper, Accidental overdose. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Gold also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Colloidal Gold with EU status "prohibited".
What clinical phase is Gold in?
No phase 1-4 clinical development badge is rendered for Gold because the matched compound identifier rows do not contain a max-phase value.